Pricing Log in Create free account

Aurinia Pharmaceuticals Inc (AUPH) vs Hemab Therapeutics Holdings, Inc. (COAG)

Aurinia Pharmaceuticals Inc and Hemab Therapeutics Holdings, Inc. are both Biotechnology companies. Aurinia Pharmaceuticals Inc and Hemab Therapeutics Holdings, Inc. are of similar size ($2.2B and $2.1B). Hemab Therapeutics Holdings, Inc. has negative trailing earnings, so its P/E is not meaningful; Aurinia Pharmaceuticals Inc trades at 6.9×. Aurinia Pharmaceuticals Inc has the higher net margin (97.7% vs 0.00%) and the higher return on invested capital (43.0% vs 0.00%). Across the 11 metrics below, Aurinia Pharmaceuticals Inc leads on 8 and Hemab Therapeutics Holdings, Inc. on 3.

Valuation

Metric AUPH COAG Biotechnology median
P/E 6.87 n/m 10.60
P/S 6.81 n/m 9.40
P/B 3.33 3.22 2.13
Price to free cash flow 12.38 n/m 25.18
EV/EBITDA 10.67 n/m 0.66
EV/Sales 5.42 n/m 9.02
Earnings yield 14.56% (110.83%) (32.88%)
Free cash flow yield 8.08% (4.97%) (23.13%)

Profitability

Metric AUPH COAG Biotechnology median
Gross margin 90.62% — 68.51%
Operating margin 44.78% 0.00% 0.00%
Net margin 97.68% 0.00% 0.00%
Free cash flow margin 55.02% 0.00% 0.00%
Return on equity 61.42% 0.00% (51.96%)
Return on assets 46.45% (31.79%) (46.06%)
Return on invested capital 42.95% 0.00% 0.00%

Growth

Metric AUPH COAG Biotechnology median
Revenue growth (TTM) 21.04% — 6.76%
EPS growth (last fiscal year) 5,075.00% — 29.88%
Revenue growth, 5-year CAGR 41.38% — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric AUPH COAG Biotechnology median
Debt to equity 0.06 0.00 0.00
Current ratio 6.12 35.85 4.97
Net debt to EBITDA (2.58) — 1.01

Dividend

Metric AUPH COAG Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric AUPH COAG Biotechnology median
Market cap 2.17b 2.13b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack